Introduction
After the completion of the first draft of the Human Genome in 2000 (National Human Genome Research Institute, 2000) , a new era of sequencing-based investigation opened the promise for tailored therapies in human health. A number of large-scale genomic-based projects have been completed since then, providing a wealth of information to mine in the discovery of etiological factors and allowing for development of diagnostic tools previously unavailable. As noted in a 2016 report from the Institute of Medicine (National Academies of Sciences, Engineering, and Medicine Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, 2016), however, one of the barriers to achieving the full potential of precision medicine is the inability to track outcomes for patients treated with molecularly targeted therapies. This inability is due both to the lack of critical information in health records and databases and to the lack of data structure that would allow integration of data from diverse sources.
Stakeholders have increasingly recognized that despite differing architectures and purposes for data collection, all non-proprietary cancer genomics repositories should share basic common elements, definitions, and standards to allow data pooling for maximum analytical power. The Center for Medical Technology Policy (CMTP), through its Green Park Collaborative (GPC), and the Molecular Evidence Development Consortium (MED-C) undertook a project to identify a core set of data elements and values essential to understanding the clinical utility of molecularly targeted therapies in oncology (core data elements [CDEs] ). Previous experiences had shown exhaustive data element sets to be of little value because potential users assessed the data collection requirements as too onerous; this effort therefore concentrated on the minimal CDE set needed for clinical interpretation of genomic data to encourage uptake and use of these key data elements.
Methods
In early 2016, a working group composed of two standards alignments task forces was established. One task force, comprised primarily of clinical experts, focused on identification of needed clinical data elements; the other, comprised primarily of data experts, centered on issues of genomic data sources, data collection feasibility, definitions, and standards. In February of 2016, the two task forces held a joint kick-off webinar, during which it was agreed that the working group's first step should be to identify prominent existing or planned oncology databases and attempt to examine their data fields. This process would help the working group address two critical questions:
(1) what data (e.g., patient characteristics, diagnosis, outcomes, etc.) are currently being collected, and (2) where can points of commonality be identified?
A total of eight organizations were approached and asked to share information about the cancer and genomic data they were collecting (or planning to collect) as well as any rules they might have regarding which elements were required to be submitted, as opposed to being optional. The data dictionaries received were cataloged and compared to identify items and methods of collection that appeared frequently. A master file was developed to enumerate the databases' elements and show where commonalities existed. Working via teleconference and email, the task forces reviewed and finalized a draft set of data elements to be presented at an inperson multi-stakeholder workshop in Baltimore, Maryland.
Held in April of 2016, the working meeting brought together more than 50 experts and stakeholders, including researchers, clinicians, patients, medical societies, life sciences companies, public and private payers, and regulators (Data S1). The goal was to discuss the proposed set of data elements and determine as a group which elements should be designated core items. Participants were divided into four pre-assigned breakout groups, and each group was instructed to discuss specific data categories (e.g., demographic data, lab values). Each data category was assigned to two or more groups. For each assigned data category, a group was asked (1) to identify data elements that should be part of an essential minimum dataset and (2) to determine the appropriate data value domains for each chosen element. At the conclusion of the breakout sessions, the groups reconvened to review the working sets of data elements in each category, discuss any differences of opinion, and attempt to reach consensus on which items were the most essential to collect. The GPC team then collected and analyzed the feedback contributed by the meeting attendees and constructed a comprehensive draft list of consensus core data elements and potential data value domain choices.
The draft CDEs and data value domains were shared with the project participants and meeting attendees using Microsoft OneDrive, which allows for live-view, anonymous online commenting. Although the status of most elements was resolved at the April meeting, for some elements it was not clear whether consensus had been reached regarding their inclusion. For those elements of unclear status, respondents were asked to use the online platform SurveyMonkey to vote on whether they should be part of the CDE set. Respondents were also encouraged to comment on the draft document in OneDrive, including responding to comments left by other participants, in order to foster dialog and to make transparent the discussions and rationales underlying the expressed views.
All respondent feedback and votes were then compiled and a final consensus set of minimal elements and data value domains was produced. The task force leads and GPC staff jointly drafted a manuscript summarizing the project process and results and distributed it, along with the final CDE set, to all participants and meeting attendees in early 2017. Recipients were then given the option of formally ''signing on'' to the manuscript to indicate their support of the consensus set. (Signing on to the manuscript does not necessarily denote an author's approval of each separate data element-in a consensus project, it is expected that any given individual's personal preferences may diverge from the consensus.)
Data Presentation Data Dictionaries
Seven organizations shared the elements and value domains of their cancer-related databases with the group. Each organization had a different setting and purpose for data collection and at least three collected data from outside the United States (Table 1) .
The number of data elements collected by each organization varied from around 40 to more than 540, and very few were common to all or even most of the dictionaries. More specifically, out of more than 400 compiled elements that were reviewed, only 7 were included in at least six of the dictionaries: (1) date (or at least year) of birth, (2) patient gender, (3) patient race, (4) survival status, (5) stage of disease, (6) biomarkers/receptors, and (7) pharmacological therapeutic agents. Only an additional 20 or so elements appeared in more than half of the dictionaries; the remaining 370 items were shared by fewer than half of the databases, and many of them were unique to a single database.
The group organized the elements in the data dictionaries into 13 categories: patient identifiers, contact information, informed consent, demographics, medical history, family history, cancer risk factors, physical examination at diagnosis, lab chemistry values, co-morbidities and medications, initial diagnosis including prognostic biomarkers, treatment episodes, and outcomes. The largest category was ''outcomes,'' with over 100 data elements, followed by ''initial diagnosis including prognostic biomarkers'' with more than 80; those two categories accounted for approximately half of all the data elements reviewed.
Consensus Data Elements
The final set of consensus data elements included 49 elements with value domain types and specific values (Data S2). Some of these elements are ancillary to more significant elements and were included because they are necessary to provide comprehension/meaning (e.g., units of measurement for height and weight).
The group decided early in the deliberative process that dates of events were key elements. Although some dictionaries asked for interval data that would have to be calculated before entry (e.g., length of time since treatment began), entering key dates instead would allow accurate computer determination of any desired interval as well as patient age at any point in the clinical care process. The precise date (as opposed to simply the month and/or year) was specified only when needed for calculating important time intervals.
The other core data elements selected fell within only 6 of the 13 identified data element categories: no elements were selected pertaining to patient identifiers, contact information, informed consent, family history, cancer risk factors, lab chemistry values, or co-morbidities and medications. The six chosen categories and data element subjects for each are provided in Table 2 .
Data Value Domains
Numeric value domains were chosen for dates and measurements. Dates were in the U.S. standard format of month, day, and year (i.e., mm/dd/yyyy) or month and year if the precise day was not needed (mm/yyyy).
In order to standardize other data elements, avoid the need to reference any external coding system, and provide ease and efficiency of use, drop-down menus were utilized wherever possible. The menu choices generally were based on existing standards where appropriate. The data value domains for ethnicity and race, for example, reflect the current Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity that are issued by the Office of Management and Budget and utilized by most federal entities, including the NIH (National Institutes of Health, 2015) . Similarly, data value domains for anatomical sites and cancer diagnoses are based on and can be mapped to ICD-O-3 Topographical and Morphological Codes (World Health Organization, 2013) . These two particular domains incorporate multiple levels of menus: the user first selects 1 of 22 higher-level organ systems or areas (e.g., oral cavity and pharynx) then selects a more specific second-level site (e.g., lip, gum, palate, etc.) and, if needed, moves to a third level to select histologic/ morphological type of cancer, each of which corresponds to an ICD-O-3 Morphological Code.
In other cases, however, drop-down menus were developed de novo to simplify choices and focus on the key information that was needed. For cause of death, for example, numerous coding systems exist that utilize highly structured and detailed levels (including ICD-10 [World Health Organization, 1990] ). Our menu, however, contains only four choices: (1) due to or related to cancer, (2) due to or related to cancer treatment, (3) not related to either cancer or cancer treatment, and (4) unknown. The detail and complexities inherent in existing systems were simply not needed for the purposes of the consensus dataset.
Finally, alphanumeric domains were used where drop-down menus were impractical or unwieldy. For instance, the core data elements relating to cancer stage include the name and version of the staging system as well as the specific stage. Given the wide variety of staging systems, including many cancer-specific systems (e.g., Gleason score for prostate cancer), the difficulty of identifying each of them, and the many different versions of each in clinical use, it was deemed unlikely that drop-down menus would be able to capture the desired information; thus, alphanumeric domains were chosen. As another example, drug treatment agents are rapidly being introduced, and patients may be taking experimental agents in clinical trials. A drop-down menu would quickly become obsolete and incapable of recording accurate data, problems that an alphanumeric domain would not engender. Names of the organizations that shared their data dictionaries with the project group and the purposes for which they were collecting or planned to collect clinical cancer genomic data. Organizations collecting at least some data from outside the United States include the European Organisation for Research and Treatment of Cancer (EORTC), Genomics England, and the National Cancer Institute's Genomic Data Commons.
The complete list of data value domain types and specifics is provided in Data S2.
Discussion
We live in an era of big data. Petabytes of information are generated every day in all fields of science. It is not a question of what we can collect but more a question of what we should collect and how well the collected items answer specific questions. The expected aims and questions to be addressed by a database or registry should determine the elements that are desired, and resource availability should inform the scope of the data collected to answer the foreseen questions. A solution formulated along the lines of collecting all available data is unrealistic and results in databases that are unequally populated and, in the end, unable to answer simple questions across projects and time. Once collected, the data in the database should be able to address the desired requirements (use-cases) for which the database was initially designed. The completeness and quality of the data will determine the database's actual usefulness.
This interplay of design versus actual reporting is a complicated balance. The complexity of data acquisition when human interaction is necessary is directly proportional to the difficulty and/or cost of obtaining the data. In most cases, costs and personnel are two major hurdles in collecting data. These concerns are relevant primarily to the collection of clinical data-molecular data do not require such decisions because once a platform is selected, the output generally will be a fixed format dependent on the platform (it is possible that the test platform or nomenclature could change).
We began the project by surveying existing data dictionaries for two specific reasons. One was to examine how other groups approached important data elements; the other was to assess how easily datasets could share similar outcomes. Although the different datasets provided to the group generally touched on the same data element categories, they did so to different extents and levels of detail, likely because of their varying missions and goals. Thus, we observed only a small set of relatively universal elements in the different datasets. Additionally, there did not appear to be any standardization in terms of method of data collection.
The largest data element categories in the data dictionaries were diagnosis (including molecular signatures) and outcomes, and our group agreed that these two areas were the most important for information collection. At the same time, however, the group had to grapple with the reality of a system with finite resources and how likely it would be to obtain key elements. The group readily accepted that the quality of certain data elements was of greater value than the quantity of others and that, in the selection process, some tradeoffs would be necessary. The decisions about which CDEs were required for molecular data interpretation were based on this foundation of understanding.
Thus, while outcome data were considered a critical data category, not all outcome fields within it were considered equally important (e.g., overall survival Of the 13 overarching categories of data used by the project group, 6 contained consensus clinical data elements and are listed in the first column along with a seventh category for relevant dates.
The particular subjects within each data category that included final core data elements are provided in the second column. Data subjects do not necessarily relate on a 1:1 basis with data elements. For example, there are three subjects within the category ''Treatment Episode'' (Therapeutic Agent and/or Modality, Intent of Treatment, and Reason for Ending Treatment) and six data elements (provided in Data S2).
was considered more important than various interim outcomes). Another tradeoff is exemplified by the decision to capture the most important type of drug administered in therapy rather than detailed drug logs. Dose intensity can be important but similarly was believed to be too onerous for most data collection efforts. Data elements that might have some prognostic value, such as certain biomarkers in certain disease states, were not considered essential because they would not result in a change of therapy and may not have been standardized. Most of the expert discussion, like these examples, centered on determining the necessity of each proposed CDE because the group believed only a reasonable number of elements could be required without compromising adherence to the standard. In summary, this proposed set of clinical data elements is not intended to be comprehensive; it is what the gathered experts judged to be a manageable, minimal, and required set that should ideally be provided in all genomic-scale projects reported. This core set can be augmented in each particular project according to the project's purpose and available resources. By insuring that these specific minimal data elements are always collected, however, and by using the standardized value domains, researchers can greatly facilitate comparison among projects and move the promise of genomic-informed personalized therapies closer to the bedside.
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